Cargando…

P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UP

Detalles Bibliográficos
Autores principales:	Tedeschi, Alessandra, Tam, Constantine, Owen, Roger, Buske, Christian, Leblond, Véronique, Dimopoulos, Meletios A., García-Sanz, Ramón, Castillo, Jorge, Trotman, Judith, Treon, Steven, Yang, Keri, Tang, Boxiong, Allewelt, Heather, Patel, Sheel, Chan, Wai, Cohen, Aileen, Schneider, Jingjing Yan, Barnes, Gisoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430046/ http://dx.doi.org/10.1097/01.HS9.0000973588.27391.ea

Ejemplares similares

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
por: Dimopoulos, M., et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022)

How to manage Waldenstrom's macroglobulinemia
por: Buske, C, et al.
Publicado: (2013)

Genomic landscape of Waldenström's macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2019)

Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
por: Muñoz, Javier, et al.
Publicado: (2022)

Treatment options for relapsed Waldenström's Macroglobulinemia
por: Grunenberg, Alexander, et al.
Publicado: (2019)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic
por: Talaulikar, Dipti, et al.
Publicado: (2020)

P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL
por: Opat, Stephen, et al.
Publicado: (2023)

P1160: RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
por: Castillo, J. J., et al.
Publicado: (2022)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate(TM) Trial
por: Trotman, Judith, et al.
Publicado: (2021)

Venetoclax in Previously Treated Waldenström Macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2022)

Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013)

Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)

Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
por: Castillo, Jorge J, et al.
Publicado: (2023)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
por: Munir, Talha, et al.
Publicado: (2023)

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
por: Castillo, Jorge J., et al.
Publicado: (2022)

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
por: An, Gang, et al.
Publicado: (2021)

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

Waldenstrom's macroglobulinemia associated with eosinophilia
por: You, Eunkyoung, et al.
Publicado: (2013)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2016)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2015)

Cutaneous macroglobulinosis with Waldenström macroglobulinemia
por: Hassab-El-Naby, Hussein M.M., et al.
Publicado: (2020)

Bone localization of Waldenstrom’s macroglobulinemia
por: Daste, Camille, et al.
Publicado: (2023)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
por: Sacco, Antonio, et al.
Publicado: (2017)

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia
por: Bouyssou, Juliette M., et al.
Publicado: (2018)

Pseudovitelliform Subfoveal Deposit in Waldenström's Macroglobulinemia
por: Brolly, Aurélie, et al.
Publicado: (2012)

Splenic re-irradiation for waldenstrőm’s macroglobulinemia
por: Wei, Zhou, et al.
Publicado: (2012)

Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia
por: Kratochvil, David, et al.
Publicado: (2012)

Clinical Features of Waldenstrom Macroglobulinemia in Korea
por: Bang, Soo-Mee, et al.
Publicado: (2004)

CNS Vasculitis Associated with Waldenström Macroglobulinemia
por: Riangwiwat, Tanawan, et al.
Publicado: (2016)

Waldenström macroglobulinemia treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2018)

Stiff-person Syndrome with Waldenström Macroglobulinemia
por: Horiuchi, Kazuhiro, et al.
Publicado: (2018)

Waldenström macroglobulinemia: biology, genetics, and therapy
por: Paludo, Jonas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2ep557p89ohdmpnhacatgf4f9g